TCM
HALO icon

Timpani Capital Management’s Halozyme HALO Stock Holding History

Timpani Capital Management’s Portfolio HALO Stock Details HALO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-103,895
Closed -$2.04M – 99
2018
Q1 		$2.04M Sell
103,895
-51,171
-33% -$991K 0.71% 64
2017
Q4 		$3.14M Buy
+155,066
New +$2.85M 1.13% 36

Other funds holding HALO

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Timpani Capital Management's HALO Position: Q2 2018 in Review

Timpani Capital Management sold out of Halozyme (HALO) in Q2 2018, closing a stake of 103,895 shares — an estimated $2.04M sold.

Timpani Capital Management first reported a position in HALO in Q4 2017 and held it in 2 quarters. The position peaked at $3.14M in Q4 2017. 193 funds tracked by Wall St. Rank hold HALO as of Q2 2018.

  • Timpani Capital Management reported no remaining Halozyme position as of Q2 2018 after selling out during the quarter.
  • Timpani Capital Management sold 103,895 Halozyme shares in Q2 2018, an estimated $2.04M.
  • Timpani Capital Management first reported a position in Halozyme in Q4 2017 and held it in 2 quarters.
  • Timpani Capital Management's Halozyme position peaked at $3.14M in Q4 2017.
  • 193 funds tracked by Wall St. Rank held Halozyme as of Q2 2018.

Based on Timpani Capital Management's 13F filing for Q2 2018, filed 10 Aug 2018.